Delcath Systems (DCTH) 10-Q 10 Nov 16 2016 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2016	Nov. 10, 2016
Document And Entity Information [Abstract]
Entity Registrant Name	DELCATH SYSTEMS, INC.
Entity Central Index Key	872,912
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		2,197,431
Document Fiscal Year Focus	2,016
Trading Symbol	DCTH
Document Fiscal Period Focus	Q3
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands		Sep. 30, 2016	Dec. 31, 2015
Current assets
Cash and cash equivalents		$ 3,689	$ 12,607
Restricted cash		23,737	0
Accounts receivables, net		342	277
Inventories		600	757
Prepaid expenses and other current assets		310	960
Deferred financing costs		489	0
Total current assets		29,167	14,601
Restricted cash, net of current portion		6,550	0
Deferred financing costs, net of current portion		122	0
Property, plant and equipment, net		1,141	1,132
Total assets		36,980	15,733
Current liabilities
Accounts payable		182	284
Accrued expenses		2,701	2,243
Warrant liability		22,502	3,785
Total current liabilities		25,385	6,312
Convertible notes payable, net of debt discount		6,413	0
Deferred Revenue		31	0
Other non-current liabilities		665	820
Total liabilities		32,494	7,132
Commitments and Contingencies
Stockholders' equity
Preferred stock, $.01 par value; 10,000,000 shares authorized; no shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively		0	0
Common stock, $.01 par value; 500,000,000 shares authorized; 1,541,043 and 1,396,348 shares issued and 1,521,933 and 1,360,239 shares outstanding at September 30, 2016 and December 31, 2015, respectively	[1]	15	14
Additional paid-in capital		275,245	269,863
Accumulated deficit		(270,703)	(261,217)
Treasury stock, at cost; 110 shares at September 30, 2016 and December 31, 2015, respectively	[1]	(51)	(51)
Accumulated other comprehensive income		(20)	(8)
Total stockholders' equity		4,486	8,601
Total liabilities and stockholders' equity		$ 36,980	$ 15,733
[1]	reflects a one-for-sixteen (1:16) reverse stock split effected on July 21, 2016

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical)	Sep. 30, 2016$ / sharesshares	Dec. 31, 2015$ / sharesshares
Statement Of Financial Position [Abstract]
Preferred stock, par value (in dollars per share) | $ / shares	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share) | $ / shares	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	500,000,000	500,000,000
Common stock, shares issued (in shares)	1,541,043	1,396,348
Common stock, shares outstanding (in shares)	1,521,933	1,360,239
Treasury stock, at cost (in shares)	110	110

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Income Statement [Abstract]
Revenue		$ 435	$ 399	$ 1,316	$ 1,308
Cost of goods sold		112	90	373	360
Gross profit		323	309	943	948
Operating expenses:
Selling, general and administrative		2,361	2,276	7,025	7,818
Research and development		2,686	1,683	5,975	4,112
Total operating expenses		5,047	3,959	13,000	11,930
Operating loss		(4,724)	(3,650)	(12,057)	(10,982)
Change in fair value of the warrant liability, net		8,680	1,253	9,171	1,414
Interest income (expense)		(4,963)	(14)	(6,584)	(39)
Other income (expense)		2	(11)	(15)	(4)
Net loss		(1,005)	(2,422)	(9,485)	(9,611)
Other comprehensive income (loss):
Foreign currency translation adjustments		(2)	(4)	(12)	(12)
Comprehensive loss		$ (1,007)	$ (2,426)	$ (9,497)	$ (9,623)
Common share data:
Basic and diluted loss per common share	[1]	$ (0.66)	$ (1.96)	$ (6.38)	$ (10.75)
Weighted average number of basic and diluted common shares outstanding	[1]	1,521,927	1,233,086	1,486,986	893,819
[1]	reflects a one-for-sixteen (1:16) reverse stock split effected on July 21, 2016

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parenthetical)	Jul. 21, 2016
Income Statement [Abstract]
Reverse stock split ratio	0.0625

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities:
Net loss	$ (9,485)	$ (9,611)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock option compensation expense	138	255
Restricted stock compensation expense	228	189
Depreciation expense	232	504
Loss on disposal of equipment	1	2
Warrant liability fair value adjustment	(9,171)	(1,414)
Non-cash interest income	(1)	(1)
Deferred revenue	31	0
Debt discount and deferred finance costs amortization	6,567	0
Changes in assets and liabilities:
Decrease in prepaid expenses and other assets	610	306
Increase in accounts receivable	(94)	(135)
Decrease (increase) in inventories	190	(62)
Increase (decrease) in accounts payable and accrued expenses	312	(2,056)
Decrease in other non-current liabilities	(155)	(165)
Net cash used in operating activities	(10,597)	(12,188)
Cash flows from investing activities:
Purchase of property, plant and equipment	(245)	(129)
Increase in restricted cash	(1,087)	0
Proceeds from sales of property, plant and equipment	0	2
Net cash used in investing activities	(1,332)	(127)
Cash flows from financing activities:
Increase in restricted cash	(29,200)	0
Net proceeds from convertible debt financing	31,436	0
Net proceeds from sale of stock and exercise of warrants	704	8,674
Net cash provided by financing activities	2,940	8,674
Foreign currency effects on cash and cash equivalents	71	(162)
Net decrease in cash and cash equivalents	(8,918)	(3,803)
Cash and cash equivalents:
Beginning of period	12,607	20,469
End of period	3,689	16,666
Supplemental non-cash activities:
Fair value of warrants issued	28,133	4,247
Fair value of warrants exercised	$ 245	$ 123

General

General	9 Months Ended
	Sep. 30, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
General	(1) General The interim condensed consolidated financial statements of Delcath Systems, Inc. (“Delcath” or the “Company”) as of and for the three months and nine months ended September 30, 2016 and 2015 should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 (“Annual Report”), which has been filed with the Securities Exchange Commission (“SEC”) and can also be found on the Company’s website (www.delcath.com). In these notes the terms “us”, “we” or “our” refer to Delcath and its consolidated subsidiaries. On July 19, 2016, shareholders of the Company approved, through a shareholder vote, an amendment to the Company’s Amended and Restated Certificate of Incorporation authorizing the Board of Directors to effect a reverse stock split of Delcath’s common stock at a ratio within a range of one-for-ten (1:10) to one-for-twenty (1:20). The reverse stock split became effective on July 21, 2016 at which time Delcath’s common stock began trading on the NASDAQ Stock Exchange on a one-for-sixteen (1:16) split-adjusted basis. All owners of record as of the open of the NASDAQ market on July 21, 2016 received one issued and outstanding share of Delcath common stock in exchange for sixteen issued and outstanding shares of Delcath common stock. No fractional shares were issued in connection with the reverse stock split. All fractional shares created by the one-for-sixteen exchange were rounded up to the next whole share. All current and prior period amounts related to shares, share prices and earnings per share, presented in these condensed consolidated financial statements and the accompanying Notes, have been restated to give retrospective presentation for the reverse stock split. Description of Business Delcath Systems, Inc. is an interventional oncology Company focused on the treatment of primary and metastatic liver cancers. Our investigational product—Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) —is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In Europe, our system is in early-stage commercial development under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT®), where it has been used at major medical centers to treat a wide range of cancers of the liver. Our primary research focus is on ocular melanoma liver metastases (mOM), intrahepatic cholangiocarcinoma (ICC), hepatocellular carcinoma (HCC or primary liver), and certain other cancers that are metastatic to the liver. We believe the disease states we are investigating represent a multi-billion dollar global market opportunity and a clear unmet medical need. Our clinical development program (CDP) for CHEMOSAT/Melphalan/HDS is comprised of: The FOCUS Clinical Trial for Patients with Hepatic Dominant Ocular Melanoma, a Global Phase 3 clinical trial that is investigating overall survival in mOM, and a Global Phase 2 clinical trial program investigating Melphalan/HDS with and without sorafenib in HCC and Melphalan/HDS in ICC. Our CDP also includes a commercial registry for CHEMOSAT non-clinical commercial cases performed in Europe and sponsorship of select investigator initiated trials (IITs) in HCC and colorectal cancer liver metastases (mCRC).. Liquidity and Operating Matters The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses since inception and has an accumulated deficit of $270.7 $1.0 $10.6 The Company’s existence is dependent upon management’s ability to obtain additional funding sources or to enter into strategic alliances. There can be no assurance that the Company’s efforts will result in the resolution of the Company’s liquidity needs. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern. The Company has incurred losses since inception. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales. As a result of issuing $35.0 million in senior secured convertible notes in June 2016, management believes that its capital resources are adequate to fund operations through the end of 2017. To the extent additional capital is not available when needed, the Company may be forced to abandon some or all of its development and commercialization efforts, which would have a material adverse effect on the prospects of the business. Operations of the Company are subject to certain risks and uncertainties, including, among others, uncertainties and risks related to clinical research, product development; regulatory approvals; technology; patents and proprietary rights; comprehensive government regulations; limited commercial manufacturing; marketing and sales experience; and dependence on key personnel. Basis of Presentation These interim condensed consolidated financial statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (GAAP) and with the SEC’s instructions to Form 10-Q and Article 10 of Regulation S-X. They include the accounts of all entities controlled by Delcath and all significant inter-company accounts and transactions have been eliminated in consolidation. The preparation of interim financial statements requires management to make assumptions and estimates that impact the amounts reported. These interim condensed consolidated financial statements, in the opinion of management, reflect all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the Company’s results of operations, financial position and cash flows for the interim periods ended September 30, 2016 and 2015; however, certain information and footnote disclosures normally included in our Annual Report have been condensed or omitted as permitted by GAAP. It is important to note that the Company’s results of operations and cash flows for interim periods are not necessarily indicative of the results of operations and cash flows to be expected for a full fiscal year or any interim period. Significant Accounting Policies A description of our significant accounting policies has been provided in Note 3 Summary of Significant Accounting Policies Deferred Revenue Deferred revenue on the accompanying condensed consolidated balance sheets includes payment received for product sales to a distributor. When obligations or contingencies remain after the products are shipped, such as training and certifying the treatment centers, revenue is deferred until the obligations or contingencies are satisfied. The Company will recognize the revenue related to product sales when its obligations under the agreement have been satisfied. Restricted Cash Cash and cash equivalents that are restricted as to withdrawal or use under the terms of certain contractual agreements are recorded as restricted cash on the accompanying condensed consolidated balance sheets. On June 13, 2016, the Company issued $35.0 million in senior secured convertible notes and received $32.2 million in cash proceeds. Under the terms of the notes, at closing, an initial tranche of $3.0 million was available for immediate use by the Company for general corporate purposes. The remaining cash proceeds of $29.2 million will be available in a tranche of $3.0 million on December 31, 2016 (‘First Release Date”) and the remainder of $26.2 million in four equal tranches to be released quarterly, beginning in January 2017 (“Subsequent Release Dates”), pursuant to an account control agreement whereby the restrictions on the proceeds are terminated when the Company meets certain equity conditions. The terms of the Notes are discussed in more detail in Note 7 of the Company’s interim condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q. The cash is deposited in an account that is not FDIC insured. Recent Accounting Pronouncements In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”) that updates the principles for recognizing revenue. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 also amends the required disclosures of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. The Company expects to adopt this guidance when effective, and does not anticipate that this guidance will materially impact its consolidated financial statements. In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements — Going Concern, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”). ASU 2014-15 requires management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the ASU (1) provides a definition of the term substantial doubt, (2) requires an evaluation every reporting period including interim periods, (3) provides principles for considering the mitigating effect of management’s plans, (4) requires certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) requires an express statement and other disclosures when substantial doubt is not alleviated, and (6) requires an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). This standard is effective for the fiscal years ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company does not anticipate that this guidance will materially impact its consolidated financial statements. In April 2015, the FASB issued ASU 2015-03, “Simplifying the Presentation of Debt Issuance Costs,” which requires debt issuance costs to be presented in the balance sheet as a direct deduction from the carrying value of the associated debt liability, consistent with the presentation of debt discounts or premiums. The ASU is effective for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. During the year 2015, the Company elected early adoption of this standard and applied the changes in its financial statements and related disclosures. In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. ASU 2015-11 more closely aligns the measurement of inventory in U.S. GAAP with the measurement of inventory in International Financial Reporting Standards by requiring companies using the first-in, first-out and average costs methods to measure inventory using the lower of cost and net realizable value, where net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. ASU 2015-11 is effective for annual reporting periods beginning after December 15, 2016 and interim periods within those fiscal years. ASU 2015-11 should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The Company does not anticipate that this guidance will materially impact its consolidated financial statements. In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740). ASU 2015-17 requires deferred tax liabilities and assets to be classified as non-current on the consolidated condensed balance sheet. ASU 2015-17 is effective for annual reporting periods beginning after December 15, 2016 and interim periods within those fiscal years and early application is permitted. ASU 2015-17 may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented. The Company does not anticipate that this guidance will materially impact its consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, Leases, which requires entities to report a right-to-use asset and liability for the obligation to make payments for all leases with the exception of those leases with a term of twelve months or less. ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018. The Company is currently evaluating the impact of the pending adoption of ASU 2016-02 on its consolidated financial statements. In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The standard is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016, and early adoption is permitted. The Company is currently evaluating the impact of the pending adoption of ASU 2016-09 on its consolidated financial statements.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2016
Inventory Disclosure [Abstract]
Inventories	(2) Inventories Inventories consist of the following: (in thousands) September 30, 2016 December 31, 2015 Raw materials $ 313 $ 360 Work-in-process 171 251 Finished goods 116 146 Total inventory $ 600 $ 757

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	9 Months Ended
	Sep. 30, 2016
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Prepaid Expenses And Other Current Assets	(3) Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following: (in thousands) September 30, 2016 December 31, 2015 Insurance premiums $ 85 $ 625 Kits for clinical use — 162 Security deposit 49 74 Other 1 176 99 Total prepaid expenses and other current assets $ 310 $ 960 1 Other consists of various prepaid expenses and other current assets, with no individual item accounting for more than 5% of prepaid expenses and other current assets at September 30, 2016 and December 31, 2015.

Property, Plant, and Equipment

Property, Plant, and Equipment	9 Months Ended
	Sep. 30, 2016
Property Plant And Equipment [Abstract]
Property, Plant, and Equipment	(4) Property, Plant, and Equipment Property, plant, and equipment consist of the following: (in thousands) September 30, 2016 December 31, 2015 Buildings and land $ 556 $ 556 Enterprise hardware and software 1,529 1,520 Leaseholds 1,520 1,305 Equipment 933 902 Furniture 355 355 Property, plant and equipment, gross 4,893 4,638 Accumulated depreciation (3,752 ) (3,506 ) Property, plant and equipment, net $ 1,141 $ 1,132 Depreciation expense for the three months and nine months ended September 30, 2016 was approximately $$0.1 million and $0.2 million, respectively, as compared to approximately $0.1 million and 0.5 million, respectively, for the same periods in 2015.

Accrued Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2016
Payables And Accruals [Abstract]
Accrued Expenses	(5) Accrued Expenses Accrued expenses consist of the following: (in thousands) September 30, 2016 December 31, 2015 Compensation, excluding taxes $ 928 $ 692 Clinical trial expenses 782 219 Professional fees 234 391 Short-term portion of lease restructuring 209 220 Other 1 548 721 Total accrued expenses $ 2,701 $ 2,243 1 Other consists of various accrued expenses, with no individual item accounting for more than 5% of current liabilities at September 30, 2016 and December 31, 2015.

Restructuring Expenses

Restructuring Expenses	9 Months Ended
	Sep. 30, 2016
Restructuring And Related Activities [Abstract]
Restructuring Expenses	(6) Restructuring Expenses In order to help reduce operating costs and more appropriately align its office space with the reduced size of its workforce, the Company entered into two sub-leases for office space at its 810 Seventh Avenue office. On May 22, 2014, the Company entered into a sub-lease agreement (“Sub-lease #1”) for approximately one-half of the office space at this location (“Suite 3500”), resulting in a lease restructuring reserve of approximately $0.9 million. On August 18, 2014, the Company entered into a sub-lease agreement (“Sub-lease #2”) for the remaining one-half of office space at its 810 Seventh Avenue office (“Suite 3505”), resulting in a lease restructuring reserve of approximately $0.7 million. As of September 30, 2016, the total remaining lease restructuring liability for its leased office space was approximately $0.9 million, of which approximately $0.2 million and $0.7 million were included in Accrued expenses and Other non-current liabilities on the condensed consolidated balance sheets, respectively. The following table provides the year-to-date activity of the Company’s restructuring reserves as of September 30, 2016: (in thousands) Lease Liability Reserve balance at December 31, 2015 $ 1,039 Charges — Payments/Utilizations (165 ) Reserve balance at September 30, 2016 $ 874

Convertible Notes Payable

Convertible Notes Payable	9 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Convertible Notes Payable	(7) Convertible Notes Payable On June 6, 2016, the Company entered into a Securities Purchase Agreement (the “SPA”) with certain investors named on the Schedule of Buyers attached to the SPA pursuant to which the Company issued $35.0 million in principal face amount of senior secured convertible notes of the Company (the “Notes”) and related Series C Warrants (the “Series C Warrants”) to purchase additional shares of the Company’s common stock, par value $0.01 per share (“Common Stock”). $35.0 million of the Notes were issued for cash proceeds of $32.2 million with an original issue discount in the amount of $2.8 million. The Notes do not bear any ordinary interest. However, interest shall commence accruing immediately upon the occurrence of, and shall continue accruing during the continuance of, an Event of Default, at 15% per annum and shall be computed on the basis of a 360-day year of twelve 30-day months and shall be payable, if applicable, in arrears for each calendar month on the first (1st) business day of each calendar month after any such interest accrues after an Event of Default. Under the terms of the Notes, at closing the Company received an initial tranche of $3.0 million for immediate use for general corporate purposes. The remaining cash proceeds of $29.2 million are being held in a restricted account and will be released to the Company from the Company’s restricted accounts in subsequent tranches subject to certain equity conditions. As security for the Company’s obligations under the Notes, $29.2 million of the total net cash proceeds is subject to a cash covenant restricting its use and requiring it to be held in a Master Restricted Account (“Master Restricted Account”) established in accordance with and pursuant to the terms and conditions of an account control agreement between the Company, the Buyers and Silicon Valley Bank (a “Controlled Account Agreement”). Subsequently, $3.0 million of the restricted cash shall become unrestricted cash on the 20 th th th In connection with the issuance of the Notes under the SPA, the Company also issued Series C Warrants, exercisable to acquire 6.8 million shares of Common Stock. On December 31, 2017, the number of Warrant Shares issuable upon exercise of the Series C Warrants will be increased by such number of Warrant Shares equal to 75% of the difference of (i) the quotient of (A) the product of (x) the exercise price as of the date of issuance (as adjusted for certain events) multiplied by (y) the number of Warrant Shares as of the date of issuance (as adjusted for certain events), divided by (B) the volume-weighted average price of the Common Stock on the maturity date, less (ii) the number of Warrant Shares as of the date of issuance (as adjusted for certain events). Each Series C Warrant will be exercisable by the holder beginning one year after the closing date and continuing for a period of five years thereafter. The Series C Warrants are exercisable at $4.83 per share of common stock, subject to adjustments for certain dilutive events. T he provisions in the Series C Warrants require the Company to account for the warrants as derivative liabilities. The Company has agreed to make amortization payments with respect to the Notes in twelve (12) equal installments beginning seven (7) months after the original date of issuance of June 13, 2016 (each, an “Installment Date”). On each installment date, assuming certain equity conditions are met, the installment payment shall, at the election of the Company, automatically be converted into shares of Common Stock at a conversion rate defined in the agreement. At any time after the issuance of the Notes, the Notes will be convertible at the election of the holder into shares of our Common Stock at a conversion price equal to $4.39, subject to adjustment as provided in the Notes. As a result of the Notes including a feature such that the conversion price is based upon a formula which includes discounts to the market price of the common stock as well as having a lower effective conversion price considering the issuance discount and the value allocated to the Series C Warrants 10.1 put options in the event of default and change in control as defined in the Notes. The value of such options was zero as the probability for such events was remote as of the issuance date and at September 30, 2016. All debt issuance costs are accounted for as a deferred asset and will be amortized over the life of the Notes. The following table summarizes the convertible notes outstanding at September 30, 2016: (in thousands) Convertible notes payable, principal $ 35,000 Debt discounts (28,587 ) Net convertible note payable $ 6,413

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2016
Stockholders Equity Note [Abstract]
Stockholders' Equity	(8) Stockholders’ Equity Stock Issuances Reverse Stock Split On July 19, 2016, shareholders of the Company approved, through a shareholder vote, an amendment to the Company’s Amended and Restated Certificate of Incorporation authorizing the Board of Directors to effect a reverse stock split of Delcath’s common stock at a ratio within a range of one-for-ten (1:10) to one-for-twenty (1:20). The reverse stock split became effective on July 21, 2016 at which time Delcath’s common stock began trading on the NASDAQ Stock Exchange on a one-for-sixteen (1:16) split-adjusted basis. All owners of record as of the open of the NASDAQ market on July 21, 2016 received one issued and outstanding share of Delcath common stock in exchange for sixteen issued and outstanding shares of Delcath common stock. No fractional shares were issued in connection with the reverse stock split. All fractional shares created by the one-for-sixteen exchange were rounded up to the next whole share. The reverse stock split had no impact on the par value per share of Delcath common stock, which remains at $0.01. All current and prior period amounts related to shares, share prices and earnings per share, presented in the Company’s interim condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q and the accompanying Notes, have been restated to give retrospective presentation for the reverse stock split. In addition, shareholders of the Company also approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 170,000,000 to 500,000,000. The previously discussed reverse stock split had no impact on the increase in authorized shares. At-the-Market (“ATM”) Programs In March 2013, the Company entered into an agreement with Cowen and Company LLC (“Cowen”) to sell shares of the Company’s common stock, par value $.01 per share, from time to time, through an ATM equity offering program having aggregate sales proceeds of $50.0 million, under which Cowen will act as sales agent. During the nine months ended September 30, 2016, the Company sold an additional 3,100 shares for net proceeds of approximately $17,500. The shares were issued pursuant to an effective registration statement on Form S-3 (333-187230). The net proceeds will be used for general corporate purposes, including, but not limited to, commercialization of our products, obtaining regulatory approvals, funding of our clinical trials, capital expenditures and working capital. As of September 30, 2016, this program is no longer active. Warrants In October 2013, the Company completed the sale of 81,875 shares of its common stock and the issuance of warrants to purchase approximately 37,000 common shares (the “2013 Warrants”) pursuant to a placement agency agreement. The Company received proceeds of $7.5 million, with net cash proceeds after related expenses from this transaction of approximately $6.9 million. Of those proceeds, the Company allocated an estimated fair value of $1.9 million to the 2013 Warrants. The exercise price is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock. At September 30, 2016, the 2013 Warrants were exercisable at $112.64 per share with approximately 37,000 warrants outstanding. The 2013 Warrants have a five-year term. In February 2015, the Company completed the sale of 153,750 shares of its common stock and the issuance of warrants to purchase 69,000 common shares (the “February 2015 Warrants”) pursuant to an underwriting agreement. The Company received proceeds of $2.6 million, with net cash proceeds after related expenses from this transaction of $2.5 million. Of those proceeds, the Company allocated an estimated fair value of $0.8 million to the February 2015 Warrants. The exercise price is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock. The exercise price of the warrants is also subject to anti-dilution adjustments for any issuance of common stock or rights to acquire common stock for consideration per share less than the exercise price of the warrants. At September 30, 2016, the February 2015 Warrants were exercisable at $3.90 per share with approximately 69,000 warrants outstanding. The February 2015 Warrants have a five-year term. In July 2015, the Company completed the sale of approximately 0.6 million Units consisting of 0.6 million shares of its common stock, Series A Warrants to purchase up to approximately 0.4 million common shares (“Series A Warrants”) and Series B Warrants to purchase Units consisting of up to approximately 0.6 million common shares (“Series B Warrants”) and 0.4 million Series A Warrants pursuant to an underwriting agreement. The Company received proceeds of $7.0 million, with net cash proceeds after related expenses from this transaction of $6.0 million. Of those proceeds the Company allocated an estimated fair value of $3.4 million to the Series A and Series B Warrants. During the nine months ended September 30, 2016, approximately 0.1 million Series B Warrants were exercised for net proceeds of approximately $0.8 million. The remaining 0.4 million Series B Warrants expired on January 29, 2016 and the remaining liability was credited to Change in the fair value of the warrant liability. As a result of the Series B Warrant exercises, an additional 0.1 million Series A Warrants were issued. The exercise price of the Series A Warrants is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock and is subject to anti-dilution adjustments for any issuance of common stock or rights to acquire common stock for consideration per share less than the exercise price of the warrants. At September 30, 2016, the Series A Warrants were exercisable at $3.90 with approximately 0.5 million warrants outstanding. The Series A Warrants have a five-year term. In June 2016, the Company entered into a Securities Purchase Agreement pursuant to which the Company issued $35.0 million in principal face amount of senior secured convertible notes of the Company (the “Notes”) and related Series C Warrants (the “Series C Warrants”) to purchase 6.8 million additional shares of the Company’s common stock. The Company allocated an estimated fair value of $27.8 million to the Series C Warrants. On December 31, 2017, the number of Warrant Shares issuable upon exercise of the Series C Warrants will be increased by such number of Warrant Shares equal to 75% of the difference of (i) the quotient of (A) the product of (x) the exercise price as of the date of issuance (as adjusted for certain events) multiplied by (y) the number of Warrant Shares as of the date of issuance (as adjusted for certain events), divided by (B) the volume-weighted average price of the Common Stock on the maturity date, less (ii) the number of Warrant Shares as of the date of issuance (as adjusted for certain events). At September 30, 2016, The Series C Warrants were exercisable at $4.83 with approximately 6.8 million warrants outstanding. The Series C Warrants will be exercisable by the holder beginning one year after the closing date and continuing for a period of five years thereafter. Stock Incentive Plans The Company established the 2004 Stock Incentive Plan and the 2009 Stock Incentive Plan (collectively, the “Plans”) under which 11,719 and 200,391 shares, respectively, have been reserved for the issuance of stock options, stock appreciation rights, restricted stock, stock grants and other equity awards. In July 2016, the total number of shares of Delcath common stock reserved for issuance under the 2009 Stock Incentive Plan was increased by 106,250 shares, from 94,141 to 200,391 shares, upon a favorable vote by the Company’s stockholders. The Plans are administered by the Compensation and Stock Option Committee of the Board of Directors which determines the individuals to whom awards shall be granted as well as the type, terms, conditions, option price and the duration of each award. As of September 30, 2016 there were 120,883 A stock option grant allows the holder of the option to purchase a share of the Company’s common stock in the future at a stated price. Options and Restricted Stock granted under the Plans vest as determined by the Company’s Compensation and Stock Option Committee. Options granted under the Plans expire over varying terms, but not more than ten years from the date of grant. For the three months and nine months ended September 30, 2016, the Company recognized compensation expense of approximately $24,000 and $0.1 million, respectively, relating to stock options granted to employees. For the same period in 2015, the Company recognized compensation expense of approximately $0.1 million and $0.3 million, respectively. There were no stock options awards granted during the nine months ended September 30, 2016. There were approximately 32,765 stock option awards granted during the same period in 2015. For the three months and nine months ended September 30, 2016, the Company recognized compensation expense of approximately $38,000 and $0.2 million, respectively, relating to restricted stock granted to employees. For the same period in 2015, the Company recognized compensation expense of approximately $0.1 million and $0.2 million, respectively. There were — shares of restricted stock granted during the nine months ended September 30, 2016. There were approximately 36,000 shares of restricted stock awards granted for the same period in 2015.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements	(9) Fair Value Measurements Derivative Warrant Liability As disclosed in Note 8 of the Company’s interim condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q, the Company allocated part of the proceeds of public offerings in 2013 and 2015 of the Company’s common stock to warrants issued in connection with those transactions. In addition, the Company recognized a discount to debt related to the initial fair value of warrants issued in connection with the June 2016 Convertible Notes discussed in further detail in Note 7 of the Company’s interim condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q. The valuation of the October 2013, February 2015, Series A and Series C warrants (collectively, the “Warrants”) was determined using option pricing models. These models use inputs such as the underlying price of the shares issued at the measurement date, volatility, risk free interest rate and expected life of the instrument. The Company has classified the Warrants as a current liability due to certain provisions relating to price adjustments and potential cash payments, as well as the holders’ ability to exercise the warrants within twelve months of the reporting date and has accounted for them as derivative instruments in accordance with ASC 815, adjusting the fair value at the end of each reporting period. Additionally, the Company has determined that the warrant derivative liability should be classified within Level 3 of the fair-value hierarchy by evaluating each input for the option pricing models against the fair-value hierarchy criteria and using the lowest level of input as the basis for the fair-value classification as called for in ASC 820. There are six inputs: closing price of Delcath stock on the day of evaluation; the exercise price of the warrants; the remaining term of the warrants; the volatility of Delcath’s stock over that term; annual rate of dividends; and the risk-free rate of return. Of those inputs, the exercise price of the warrants and the remaining term are readily observable in the warrant agreements. The annual rate of dividends is based on the Company’s historical practice of not granting dividends. The closing price of Delcath stock would fall under Level 1 of the fair-value hierarchy as it is a quoted price in an active market (ASC 820-10). The risk-free rate of return is a Level 2 input as defined in ASC 820-10, while the historical volatility is a Level 3 input as defined in ASC 820. Since the lowest level input is a Level 3, Delcath determined the warrant derivative liability is most appropriately classified within Level 3 of the fair value hierarchy. For the three months and nine months ended September 30, 2016, the Company recorded pre-tax derivative warrant income of $8.7 million and pre-tax derivative income of $9.2 million, respectively. The resulting derivative warrant liabilities totaled $22.5 million at September 30, 2016. Management expects that the Warrants will either be exercised or expire worthless. The fair value of the Warrants at September 30, 2016 was determined by using option pricing models with the following assumptions: Series C Warrants Series A Warrants February 2015 Warrants October 2013 Warrants Expected volatility 91.93% 96.65% 99.65% 91.70% Risk-free interest rates 1.28% 1.01% 0.95% 0.76% Expected life (in years) 5.70 3.81 3.38 2.08 The table below presents the Company’s assets and liabilities measured at fair value on a recurring basis as of September 30, 2016, aggregated by the level in the fair value hierarchy within which those measurements fall in accordance with ASC 820. Assets and Liabilities Measured at Fair Value on a Recurring Basis (in thousands) Level 1 Level 2 Level 3 Balance at September 30, 2016 Liabilities Derivative instrument liabilities $ — $ — $ 22,502 $ 22,502 For the periods ended September 30, 2016 and 2015, there were no transfers in or out of Level 1, 2 or 3 inputs. The table below presents the activity within Level 3 of the fair value hierarchy for the nine months ended September 30, 2016: Fair Value Measurements Using Significant Unobservable Inputs (Level 3) (in thousands) Warrant Liability Balance at December 31, 2015 $ 3,785 Total change in the liability included in earnings (9,171 ) Fair value of warrants issued 28,133 Fair value of warrants exercised (245 ) Balance at September 30, 2016 $ 22,502

Net Loss per Common Share

Net Loss per Common Share	9 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Net Loss per Common Share	(10) Net Loss per Common Share Basic net loss per share is determined by dividing net loss by the weighted average shares of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is determined by dividing net loss by diluted weighted average shares outstanding. Diluted weighted average shares reflects the dilutive effect, if any, of potentially dilutive common shares, such as stock options and warrants calculated using the treasury stock method. In periods with reported net operating losses, all common stock options and warrants are generally deemed anti-dilutive such that basic net loss per share and diluted net loss per share are equal. The following potentially dilutive securities were excluded from the computation of earnings per share as of September 30, 2016 and 2015 because their effects would be anti-dilutive: September 30, 2016 2015 Stock options 41,356 47,884 Unvested restricted shares 19,000 36,006 Warrants 7,427,510 1,128,688 Total 7,487,866 1,212,578

Taxes

Taxes	9 Months Ended
	Sep. 30, 2016
Income Tax Disclosure [Abstract]
Taxes	(11) Taxes As discussed in Note 13 Income Taxes The Company is subject to income tax in the U.S., as well as various state and international jurisdictions. During the third quarter of 2015, the Company was notified by the Internal Revenue Service that they will be examining the tax return for calendar year 2013. The effect of the outcome cannot be reasonably estimated as the exam is presently ongoing. However, the Company does not expect any material change to its financial statements as a result of this audit. Any proposed adjustments would result in an adjustment to the net operating loss carryforward for which a valuation allowance has been provided against the full amount. The Company has not been audited by the international tax authorities or any states in connection with income taxes. The Company’s New York State tax returns have been subject to annual desk reviews which have resulted in insignificant adjustments to the related franchise tax liabilities and credits. The Company’s tax years generally remain open to examination for all federal, state and foreign tax matters until its net operating loss carryforwards are utilized and the applicable statutes of limitation have expired. The federal and state tax authorities can generally reduce a net operating loss (but not create taxable income) for a period outside the statute of limitations in order to determine the correct amount of net operating loss which may be allowed as a deduction against income for a period within the statute of limitations.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2016
Subsequent Events [Abstract]
Subsequent Events	(12) Subsequent Events On September 30, 2016 the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Roth Capital Partners, LLC, as Underwriter (the “Underwriter”). The Underwriting Agreement provided for the sale to the Underwriter of 425,000 units consisting of 425,000 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), and 148,750 warrants at price of $3.00 per unit. The offering closed on October 5, 2016. The warrants are exercisable beginning on the date of issuance and will expire on October 5, 2021. The exercise price of the warrants is $3.00 per share of Common Stock, subject to certain adjustments. The net proceeds to the Company from the offering are approximately $1.1 million after underwriting discounts and commissions and other estimated offering expenses payable by the Company, and excluding any proceeds the Company may receive upon exercise of the warrants issued in the offering. As a result, the exercise price of the February 2015 Warrants and the Series A Warrants has been adjusted to $2.99. .

General (Policies)

General (Policies)	9 Months Ended
	Sep. 30, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Liquidity and Operating Matters	Liquidity and Operating Matters The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses since inception and has an accumulated deficit of $270.7 $1.0 $10.6 The Company’s existence is dependent upon management’s ability to obtain additional funding sources or to enter into strategic alliances. There can be no assurance that the Company’s efforts will result in the resolution of the Company’s liquidity needs. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern. The Company has incurred losses since inception. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales. As a result of issuing $35.0 million in senior secured convertible notes in June 2016, management believes that its capital resources are adequate to fund operations through the end of 2017. To the extent additional capital is not available when needed, the Company may be forced to abandon some or all of its development and commercialization efforts, which would have a material adverse effect on the prospects of the business. Operations of the Company are subject to certain risks and uncertainties, including, among others, uncertainties and risks related to clinical research, product development; regulatory approvals; technology; patents and proprietary rights; comprehensive government regulations; limited commercial manufacturing; marketing and sales experience; and dependence on key personnel.
Basis of Presentation	Basis of Presentation These interim condensed consolidated financial statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (GAAP) and with the SEC’s instructions to Form 10-Q and Article 10 of Regulation S-X. They include the accounts of all entities controlled by Delcath and all significant inter-company accounts and transactions have been eliminated in consolidation. The preparation of interim financial statements requires management to make assumptions and estimates that impact the amounts reported. These interim condensed consolidated financial statements, in the opinion of management, reflect all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the Company’s results of operations, financial position and cash flows for the interim periods ended September 30, 2016 and 2015; however, certain information and footnote disclosures normally included in our Annual Report have been condensed or omitted as permitted by GAAP. It is important to note that the Company’s results of operations and cash flows for interim periods are not necessarily indicative of the results of operations and cash flows to be expected for a full fiscal year or any interim period.
Deferred Revenue	Deferred Revenue Deferred revenue on the accompanying condensed consolidated balance sheets includes payment received for product sales to a distributor. When obligations or contingencies remain after the products are shipped, such as training and certifying the treatment centers, revenue is deferred until the obligations or contingencies are satisfied. The Company will recognize the revenue related to product sales when its obligations under the agreement have been satisfied.
Restricted Cash	Restricted Cash Cash and cash equivalents that are restricted as to withdrawal or use under the terms of certain contractual agreements are recorded as restricted cash on the accompanying condensed consolidated balance sheets. On June 13, 2016, the Company issued $35.0 million in senior secured convertible notes and received $32.2 million in cash proceeds. Under the terms of the notes, at closing, an initial tranche of $3.0 million was available for immediate use by the Company for general corporate purposes. The remaining cash proceeds of $29.2 million will be available in a tranche of $3.0 million on December 31, 2016 (‘First Release Date”) and the remainder of $26.2 million in four equal tranches to be released quarterly, beginning in January 2017 (“Subsequent Release Dates”), pursuant to an account control agreement whereby the restrictions on the proceeds are terminated when the Company meets certain equity conditions. The terms of the Notes are discussed in more detail in Note 7 of the Company’s interim condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q. The cash is deposited in an account that is not FDIC insured.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”) that updates the principles for recognizing revenue. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 also amends the required disclosures of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. The Company expects to adopt this guidance when effective, and does not anticipate that this guidance will materially impact its consolidated financial statements. In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements — Going Concern, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”). ASU 2014-15 requires management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the ASU (1) provides a definition of the term substantial doubt, (2) requires an evaluation every reporting period including interim periods, (3) provides principles for considering the mitigating effect of management’s plans, (4) requires certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) requires an express statement and other disclosures when substantial doubt is not alleviated, and (6) requires an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). This standard is effective for the fiscal years ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company does not anticipate that this guidance will materially impact its consolidated financial statements. In April 2015, the FASB issued ASU 2015-03, “Simplifying the Presentation of Debt Issuance Costs,” which requires debt issuance costs to be presented in the balance sheet as a direct deduction from the carrying value of the associated debt liability, consistent with the presentation of debt discounts or premiums. The ASU is effective for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. During the year 2015, the Company elected early adoption of this standard and applied the changes in its financial statements and related disclosures. In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. ASU 2015-11 more closely aligns the measurement of inventory in U.S. GAAP with the measurement of inventory in International Financial Reporting Standards by requiring companies using the first-in, first-out and average costs methods to measure inventory using the lower of cost and net realizable value, where net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. ASU 2015-11 is effective for annual reporting periods beginning after December 15, 2016 and interim periods within those fiscal years. ASU 2015-11 should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The Company does not anticipate that this guidance will materially impact its consolidated financial statements. In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740). ASU 2015-17 requires deferred tax liabilities and assets to be classified as non-current on the consolidated condensed balance sheet. ASU 2015-17 is effective for annual reporting periods beginning after December 15, 2016 and interim periods within those fiscal years and early application is permitted. ASU 2015-17 may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented. The Company does not anticipate that this guidance will materially impact its consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, Leases, which requires entities to report a right-to-use asset and liability for the obligation to make payments for all leases with the exception of those leases with a term of twelve months or less. ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018. The Company is currently evaluating the impact of the pending adoption of ASU 2016-02 on its consolidated financial statements. In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The standard is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016, and early adoption is permitted. The Company is currently evaluating the impact of the pending adoption of ASU 2016-09 on its consolidated financial statements.

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2016
Inventory Disclosure [Abstract]
Schedule of inventories	Inventories consist of the following: (in thousands) September 30, 2016 December 31, 2015 Raw materials $ 313 $ 360 Work-in-process 171 251 Finished goods 116 146 Total inventory $ 600 $ 757

Prepaid Expenses and Other Cu21

Prepaid Expenses and Other Current Assets (Tables)	9 Months Ended
	Sep. 30, 2016
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consist of the following: (in thousands) September 30, 2016 December 31, 2015 Insurance premiums $ 85 $ 625 Kits for clinical use — 162 Security deposit 49 74 Other 1 176 99 Total prepaid expenses and other current assets $ 310 $ 960

Property, Plant, and Equipment

Property, Plant, and Equipment (Tables)	9 Months Ended
	Sep. 30, 2016
Property Plant And Equipment [Abstract]
Components of property, plant and equipment	Property, plant, and equipment consist of the following: (in thousands) September 30, 2016 December 31, 2015 Buildings and land $ 556 $ 556 Enterprise hardware and software 1,529 1,520 Leaseholds 1,520 1,305 Equipment 933 902 Furniture 355 355 Property, plant and equipment, gross 4,893 4,638 Accumulated depreciation (3,752 ) (3,506 ) Property, plant and equipment, net $ 1,141 $ 1,132

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2016
Payables And Accruals [Abstract]
Schedule of accrued expenses	Accrued expenses consist of the following: (in thousands) September 30, 2016 December 31, 2015 Compensation, excluding taxes $ 928 $ 692 Clinical trial expenses 782 219 Professional fees 234 391 Short-term portion of lease restructuring 209 220 Other 1 548 721 Total accrued expenses $ 2,701 $ 2,243 1 Other consists of various accrued expenses, with no individual item accounting for more than 5% of current liabilities at September 30, 2016 and December 31, 2015.

Restructuring Expenses (Tables)

Restructuring Expenses (Tables)	9 Months Ended
	Sep. 30, 2016
Restructuring And Related Activities [Abstract]
Schedule of restructuring and related costs	The following table provides the year-to-date activity of the Company’s restructuring reserves as of September 30, 2016: (in thousands) Lease Liability Reserve balance at December 31, 2015 $ 1,039 Charges — Payments/Utilizations (165 ) Reserve balance at September 30, 2016 $ 874

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Summary of Convertible Notes Outstanding	The following table summarizes the convertible notes outstanding at September 30, 2016: (in thousands) Convertible notes payable, principal $ 35,000 Debt discounts (28,587 ) Net convertible note payable $ 6,413

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Schedule of fair value of the warrants	The fair value of the Warrants at September 30, 2016 was determined by using option pricing models with the following assumptions: Series C Warrants Series A Warrants February 2015 Warrants October 2013 Warrants Expected volatility 91.93% 96.65% 99.65% 91.70% Risk-free interest rates 1.28% 1.01% 0.95% 0.76% Expected life (in years) 5.70 3.81 3.38 2.08
Assets and liabilities measured at fair value on a recurring basis	The table below presents the Company’s assets and liabilities measured at fair value on a recurring basis as of September 30, 2016, aggregated by the level in the fair value hierarchy within which those measurements fall in accordance with ASC 820. Assets and Liabilities Measured at Fair Value on a Recurring Basis (in thousands) Level 1 Level 2 Level 3 Balance at September 30, 2016 Liabilities Derivative instrument liabilities $ — $ — $ 22,502 $ 22,502
Fair value measurements using significant unobservable inputs	The table below presents the activity within Level 3 of the fair value hierarchy for the nine months ended September 30, 2016: Fair Value Measurements Using Significant Unobservable Inputs (Level 3) (in thousands) Warrant Liability Balance at December 31, 2015 $ 3,785 Total change in the liability included in earnings (9,171 ) Fair value of warrants issued 28,133 Fair value of warrants exercised (245 ) Balance at September 30, 2016 $ 22,502

Net Loss per Common Share (Tabl

Net Loss per Common Share (Tables)	9 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Anti-dilutive securities excluded from the computation of earnings per share	The following potentially dilutive securities were excluded from the computation of earnings per share as of September 30, 2016 and 2015 because their effects would be anti-dilutive: September 30, 2016 2015 Stock options 41,356 47,884 Unvested restricted shares 19,000 36,006 Warrants 7,427,510 1,128,688 Total 7,487,866 1,212,578

General - Additional Informatio

General - Additional Information (Details)	Jul. 21, 2016shares	Jul. 19, 2016	Jun. 13, 2016USD ($)	Jun. 06, 2016USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Jun. 30, 2016USD ($)	Dec. 31, 2015USD ($)
Class Of Stock [Line Items]
Reverse stock split ratio	0.0625
Reverse stock split ratio, description							On July 19, 2016, shareholders of the Company approved, through a shareholder vote, an amendment to the Company’s Amended and Restated Certificate of Incorporation authorizing the Board of Directors to effect a reverse stock split of Delcath’s common stock at a ratio within a range of one-for-ten (1:10) to one-for-twenty (1:20). The reverse stock split became effective on July 21, 2016 at which time Delcath’s common stock began trading on the NASDAQ Stock Exchange on a one-for-sixteen (1:16) split-adjusted basis. All owners of record as of the open of the NASDAQ market on July 21, 2016 received one issued and outstanding share of Delcath common stock in exchange for sixteen issued and outstanding shares of Delcath common stock.
Number of fractional shares were issued in connection with the reverse stock split | shares	0
Reverse stock split effective date							Jul. 21, 2016
Net loss					$ 1,005,000	$ 2,422,000	$ 9,485,000	$ 9,611,000
Net cash used in operating activities							10,597,000	$ 12,188,000
Accumulated deficit					270,703,000		270,703,000			$ 261,217,000
Senior Secured Convertible Notes [Member]
Class Of Stock [Line Items]
Debt instrument, principal face amount					$ 35,000,000		$ 35,000,000		$ 35,000,000
Senior Secured Convertible Notes [Member] | Series C Warrants [Member]
Class Of Stock [Line Items]
Debt instrument, principal face amount									$ 35,000,000
Senior Secured Convertible Notes [Member] | Securities Purchase Agreement [Member]
Class Of Stock [Line Items]
Debt instrument, principal face amount			$ 35,000,000	$ 35,000,000
Proceeds from issuance of notes available for general corporate purposes			3,000,000	3,000,000
Cash proceeds from notes held			29,200,000	29,200,000
Senior Secured Convertible Notes [Member] | Securities Purchase Agreement [Member] | First Release Date on December 31, 2016 [Member]
Class Of Stock [Line Items]
Cash proceeds from notes held			3,000,000	3,000,000
Senior Secured Convertible Notes [Member] | Securities Purchase Agreement [Member] | Subsequent Release Dates Beginning in January 2017 [Member]
Class Of Stock [Line Items]
Cash proceeds from notes held			26,200,000	26,200,000
Senior Secured Convertible Notes [Member] | Securities Purchase Agreement [Member] | Series C Warrants [Member]
Class Of Stock [Line Items]
Proceeds from issuance of notes			$ 32,200,000	$ 32,200,000
Minimum [Member]
Class Of Stock [Line Items]
Reverse stock split ratio		0.1
Maximum [Member]
Class Of Stock [Line Items]
Reverse stock split ratio		0.05

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Raw materials	$ 313	$ 360
Work-in-process	171	251
Finished goods	116	146
Total inventory	$ 600	$ 757

Prepaid Expenses and Other Cu30

Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Prepaid Expense And Other Assets Current [Abstract]
Insurance premiums	$ 85	$ 625
Kits for clinical use		162
Security deposit	49	74
Other	176	99
Total prepaid expenses and other current assets	$ 310	$ 960

Prepaid Expenses and Other Cu31

Prepaid Expenses and Other Current Assets - Additional Information (Details)	Sep. 30, 2016	Dec. 31, 2015
Prepaid Expense And Other Assets Current [Abstract]
Maximum percentage of prepaid expenses and other current assets (in hundredths)	5.00%	5.00%

Property, Plant, and Equipmen32

Property, Plant, and Equipment - Components of Property, Plant, and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 4,893	$ 4,638
Accumulated depreciation	(3,752)	(3,506)
Property, plant and equipment, net	1,141	1,132
Buildings and Land [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	556	556
Enterprise Hardware and Software [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	1,529	1,520
Leaseholds [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	1,520	1,305
Equipment [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	933	902
Furniture [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 355	$ 355

Property, Plant, and Equipmen33

Property, Plant, and Equipment - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Property Plant And Equipment [Abstract]
Depreciation expense	$ 100	$ 100	$ 232	$ 504

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Payables And Accruals [Abstract]
Compensation, excluding taxes	$ 928	$ 692
Clinical trial expenses	782	219
Professional fees	234	391
Short-term portion of lease restructuring	209	220
Other	548	721
Total accrued expenses	$ 2,701	$ 2,243

Accrued Expenses - Schedule o35

Accrued Expenses - Schedule of Accrued Expenses (Parenthetical) (Details)	Sep. 30, 2016	Dec. 31, 2015
Payables And Accruals [Abstract]
Maximum percentage of current liabilities accrued (in hundredths)	5.00%	5.00%

Restructuring Expenses - Additi

Restructuring Expenses - Additional Information (Details) $ in Thousands	Aug. 18, 2014USD ($)	May 22, 2014USD ($)	Sep. 30, 2016USD ($)Lease	Dec. 31, 2015USD ($)
Property Subject to Operating Lease [Member]
Restructuring Cost And Reserve [Line Items]
Number of sub leases | Lease			2
Restructuring reserve balance			$ 874	$ 1,039
Sub-lease 1 [Member] | Facility Closing [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring reserve charges		$ 900
Sub Lease 2 [Member] | Facility Closing [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring reserve charges	$ 700
Other non-current liabilities [Member] | Property Subject to Operating Lease [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring reserve balance			700
Accrued Expenses [Member] | Property Subject to Operating Lease [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring reserve balance			$ 200

Restructuring Expenses - Schedu

Restructuring Expenses - Schedule of Restructuring and Related Costs (Details) - Lease Liability [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2016USD ($)
Restructuring Cost And Reserve [Line Items]
Restructuring reserve balance	$ 1,039
Payments/Utilizations	(165)
Restructuring reserve balance	$ 874

Convertible Notes Payable - Add

Convertible Notes Payable - Additional Information (Details) $ / shares in Units, shares in Millions	Jun. 13, 2016USD ($)	Jun. 06, 2016USD ($)Installment$ / sharesshares	Sep. 30, 2016USD ($)$ / shares	Dec. 31, 2017	Jun. 30, 2016USD ($)
Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Debt instrument, principal face amount			$ 35,000,000		$ 35,000,000
Debt discount on senior notes			28,587,000
Senior Secured Convertible Notes [Member] | Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, principal face amount	$ 35,000,000	$ 35,000,000
Debt discount on senior notes		$ 2,800,000	$ 35,000,000
Interest rate upon default			0.00%
Rate of interest in event of default		15.00%
Debt instrument interest rate computation terms			The Notes do not bear any ordinary interest. However, interest shall commence accruing immediately upon the occurrence of, and shall continue accruing during the continuance of, an Event of Default, at 15% per annum and shall be computed on the basis of a 360-day year of twelve 30-day months and shall be payable
Proceeds from issuance of notes available for general corporate purposes	3,000,000	$ 3,000,000
Net cash proceeds from notes held in master restricted account as security	$ 29,200,000	$ 29,200,000
Maturity date of notes		Dec. 29, 2017
Amortization payments number of equal installments | Installment		12
Period after original date of issuance of notes for which amortization payment begins	7 months
Debt instrument, original issuance date			Jun. 13, 2016
Debt instrument, conversion price | $ / shares		$ 4.39
Debt discount amortization			$ 10,100,000
Beneficial conversion feature			4,400,000
Debt instrument, put options issued on default and change in control, value			$ 0
Senior Secured Convertible Notes [Member] | Securities Purchase Agreement [Member] | Unrestricted On 20th Trading Day After Stockholder Approval [Member]
Debt Instrument [Line Items]
Net cash proceeds from notes held in master restricted account as security	$ 3,000,000	$ 3,000,000
Senior Secured Convertible Notes [Member] | Securities Purchase Agreement [Member] | Unrestricted After Starting 30th Trading Day After Trigger Date [Member]
Debt Instrument [Line Items]
Net cash proceeds from notes held in master restricted account as security	26,200,000	26,200,000
Senior Secured Convertible Notes [Member] | Securities Purchase Agreement [Member] | Restricted Cash [Member]
Debt Instrument [Line Items]
Proceeds from issuance of notes and warrants		$ 29,200,000
Series C Warrants [Member]
Debt Instrument [Line Items]
Warrants exercise price per share | $ / shares			$ 4.83
Series C Warrants [Member] | Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Additional issuance of common stock purchase price per share. | $ / shares		$ 0.01
Shares issuable upon warrants exercised description			On December 31, 2017, the number of Warrant Shares issuable upon exercise of the Series C Warrants will be increased by such number of Warrant Shares equal to 75% of the difference of (i) the quotient of (A) the product of (x) the exercise price as of the date of issuance (as adjusted for certain events) multiplied by (y) the number of Warrant Shares as of the date of issuance (as adjusted for certain events), divided by (B) the volume-weighted average price of the Common Stock on the maturity date, less (ii) the number of Warrant Shares as of the date of issuance (as adjusted for certain events).
Warrants exercise price per share | $ / shares		$ 4.83
Warrant exercisable term description			Each Series C Warrant will be exercisable by the holder beginning one year after the closing date and continuing for a period of five years thereafter.
Vesting period to exercise warrants		1 year
warrant exercisable period after vesting		5 years
Series C Warrants [Member] | Securities Purchase Agreement [Member] | Scenario, Forecast [Member]
Debt Instrument [Line Items]
Conditional percentage of increase in number of shares issuable upon exercise of warrants				75.00%
Series C Warrants [Member] | Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Debt instrument, principal face amount					$ 35,000,000
Series C Warrants [Member] | Senior Secured Convertible Notes [Member] | Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Proceeds from issuance of notes and warrants	$ 32,200,000	$ 32,200,000
Shares issuable upon warrants exercised | shares		6.8

Convertible Notes Payable - Sum

Convertible Notes Payable - Summary of Convertible Notes Outstanding (Details) - Senior Secured Convertible Notes [Member] - USD ($)	Sep. 30, 2016	Jun. 30, 2016
Debt Instrument [Line Items]
Convertible notes payable, principal	$ 35,000,000	$ 35,000,000
Debt discounts	(28,587,000)
Net convertible note payable	$ 6,413,000

Stockholders' Equity - Reverse

Stockholders' Equity - Reverse Stock Split - Additional Information (Details)	Jul. 21, 2016$ / sharesshares	Jul. 19, 2016shares	Sep. 30, 2016$ / sharesshares	Jul. 18, 2016shares	Dec. 31, 2015$ / sharesshares
Stockholders Equity Note [Line Items]
Reverse stock split ratio	0.0625
Number of fractional shares were issued in connection with the reverse stock split	0
Common stock, par value (in dollars per share) | $ / shares	$ 0.01		$ 0.01		$ 0.01
Common stock, shares authorized (in shares)		500,000,000	500,000,000	170,000,000	500,000,000
Minimum [Member]
Stockholders Equity Note [Line Items]
Reverse stock split ratio		0.1
Maximum [Member]
Stockholders Equity Note [Line Items]
Reverse stock split ratio		0.05

Stockholders' Equity - Stock Is

Stockholders' Equity - Stock Issuances - Additional Information (Details) - USD ($)	1 Months Ended			9 Months Ended
	Jul. 31, 2015	Feb. 28, 2015	Oct. 31, 2013	Sep. 30, 2016	Jul. 21, 2016	Dec. 31, 2015	Mar. 31, 2013
Stockholders Equity Note [Line Items]
Common stock, par value (in dollars per share)				$ 0.01	$ 0.01	$ 0.01
Sale of common stock, net of expenses (in shares)	600,000	153,750	81,875
Proceeds of common stock issued, net of related expenses	$ 6,000,000
ATM Programs [Member] | Cowen and Company, LLC [Member]
Stockholders Equity Note [Line Items]
Common stock, par value (in dollars per share)							$ 0.01
Aggregate proceeds from sale of common stock under equity offering program, maximum							$ 50,000,000
Sale of common stock, net of expenses (in shares)				3,100
Proceeds of common stock issued, net of related expenses				$ 17,500

Stockholders' Equity - Warrants

Stockholders' Equity - Warrants -Additional Information (Details) - USD ($)	1 Months Ended				9 Months Ended
	Jun. 30, 2016	Jul. 31, 2015	Feb. 28, 2015	Oct. 31, 2013	Sep. 30, 2016
Class Of Warrant Or Right [Line Items]
Sale of common stock, net of expenses (in shares)		600,000	153,750	81,875
Proceeds from issuance of private placement			$ 2,600,000	$ 7,500,000
Net proceeds from issuance of private placement			$ 2,500,000	$ 6,900,000
Sale of units to underwriter		600,000
Proceeds of common stock issued, net of related expenses		$ 6,000,000
Series A Common Stock Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrants exercisable per share price (in dollars per share)					$ 3.90
Number of warrants outstanding (in shares)					500,000
Number of warrants converted		400,000			100,000
Gross proceeds from underwriting offering		$ 7,000,000
Warrants expiry period					5 years
Series B Common Stock Warrants [Member]
Class Of Warrant Or Right [Line Items]
Number of warrants converted		600,000
Warrants exercised (in shares)					100,000
Net proceeds from exercise of warrants					$ 800,000
Remaining outstanding warrants expired					400,000
Warrants expiration date					Jan. 29, 2016
Series A and B Common Stock Warrants [Member]
Class Of Warrant Or Right [Line Items]
Value of warrants issued		$ 3,400,000
Senior Secured Convertible Notes [Member]
Class Of Warrant Or Right [Line Items]
Debt instrument, principal face amount	$ 35,000,000				$ 35,000,000
2013 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrants issued (in shares)				37,000
Value of warrants issued				$ 1,900,000
Warrants exercisable per share price (in dollars per share)					$ 112.64
Number of warrants outstanding (in shares)					37,000
Term period for warrants					5 years
Series C Warrants [Member]
Class Of Warrant Or Right [Line Items]
Value of warrants issued	$ 27,800,000
Warrants exercisable per share price (in dollars per share)					$ 4.83
Number of warrants outstanding (in shares)					6,800,000
Percentage of increased number of warrant shares issuable upon exercise					75.00%
Description of warrant issued upon exercise					On December 31, 2017, the number of Warrant Shares issuable upon exercise of the Series C Warrants will be increased by such number of Warrant Shares equal to 75% of the difference of (i) the quotient of (A) the product of (x) the exercise price as of the date of issuance (as adjusted for certain events) multiplied by (y) the number of Warrant Shares as of the date of issuance (as adjusted for certain events), divided by (B) the volume-weighted average price of the Common Stock on the maturity date, less (ii) the number of Warrant Shares as of the date of issuance (as adjusted for certain events).
Warrants holding period	1 year
Warrants exercisable period	5 years
Series C Warrants [Member] | Senior Secured Convertible Notes [Member]
Class Of Warrant Or Right [Line Items]
Number of warrants converted	6,800,000
Debt instrument, principal face amount	$ 35,000,000
February 2015 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrants issued (in shares)			69,000
Value of warrants issued			$ 800,000
Warrants exercisable per share price (in dollars per share)					$ 3.90
Number of warrants outstanding (in shares)					69,000
Term period for warrants					5 years

Stockholders' Equity - Stock In

Stockholders' Equity - Stock Incentive Plans - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Jul. 31, 2016	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option compensation expense				$ 138,000	$ 255,000
Restricted stock compensation expense				228,000	189,000
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option compensation expense		$ 24,000	$ 100,000	$ 100,000	$ 300,000
Stock options granted				0	32,765
Stock Options [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options granted, term				10 years
Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted					36,000
Restricted stock compensation expense		$ 38,000	$ 100,000	$ 200,000	$ 200,000
2004 Stock Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserved for the issuance (in shares)		11,719		11,719
2009 Stock Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserved for the issuance (in shares)	94,141	200,391		200,391
Increased number of shares (in shares)	106,250
Shares available for grant		120,883		120,883

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2016USD ($)Input	Sep. 30, 2015USD ($)	Dec. 31, 2015USD ($)
Fair Value Disclosures [Abstract]
Number of inputs used for valuation of warrants | Input			6
Derivative warrant liability [Abstract]
Warrant liability fair value adjustment	$ (8,680)	$ (1,253)	$ (9,171)	$ (1,414)
Derivative warrant liabilities	$ 22,502		$ 22,502		$ 3,785

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Fair Value of Warrants (Details)	9 Months Ended
	Sep. 30, 2016
Series C Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected volatility (in hundredths)	91.93%
Risk-free interest rates (in hundredths)	1.28%
Expected life (in years)	5 years 8 months 12 days
Series A Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected volatility (in hundredths)	96.65%
Risk-free interest rates (in hundredths)	1.01%
Expected life (in years)	3 years 9 months 22 days
February 2015 Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected volatility (in hundredths)	99.65%
Risk-free interest rates (in hundredths)	0.95%
Expected life (in years)	3 years 4 months 17 days
October 2013 Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected volatility (in hundredths)	91.70%
Risk-free interest rates (in hundredths)	0.76%
Expected life (in years)	2 years 29 days

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Recurring [Member] - Derivative Instruments Liabilities [Member] $ in Thousands	Sep. 30, 2016USD ($)
Liabilities [Abstract]
Total Liabilities	$ 22,502
Level 3 [Member]
Liabilities [Abstract]
Total Liabilities	$ 22,502

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value Measurements Using Significant Unobservable Inputs (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) [Roll Forward]
Balance at December 31, 2015	$ 3,785
Total change in the liability included in earnings	(9,171)
Fair value of warrants issued	28,133	$ 4,247
Fair value of warrants exercised	(245)	$ (123)
Balance at September 30, 2016	$ 22,502

Net Loss per Common Share - Ant

Net Loss per Common Share - Anti-Dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	7,487,866	1,212,578
Stock Options [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	41,356	47,884
Unvested Restricted Shares [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	19,000	36,006
Warrants [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	7,427,510	1,128,688

Subsequent Events (Details)

Subsequent Events (Details) - USD ($) $ / shares in Units, $ in Thousands	Sep. 30, 2016	Jul. 31, 2015	Feb. 28, 2015	Oct. 31, 2013	Sep. 30, 2016	Sep. 30, 2015	Jul. 21, 2016	Dec. 31, 2015
Subsequent Event [Line Items]
Sale of common stock share		600,000	153,750	81,875
Sale of units to underwriter		600,000
Common stock, par value (in dollars per share)	$ 0.01				$ 0.01		$ 0.01	$ 0.01
Net proceeds from sale of stock and exercise of warrants					$ 704	$ 8,674
February 2015 Warrants [Member]
Subsequent Event [Line Items]
Number of warrants outstanding (in shares)	69,000				69,000
Warrants exercise price per share	$ 3.90				$ 3.90
Underwriting Agreement [Member]
Subsequent Event [Line Items]
Sale of common stock share	425,000
Sale of units to underwriter	425,000
Common stock, par value (in dollars per share)	$ 0.01				$ 0.01
Number of warrants outstanding (in shares)	148,750				148,750
Net proceeds from sale of stock and exercise of warrants	$ 1,100
Warrants expiration date	Oct. 5, 2021
Warrants exercise price per share	$ 3				$ 3
Underwriting Agreement [Member] | February 2015 Warrants [Member]
Subsequent Event [Line Items]
Adjusted exercise price of warrants	2.99				2.99
Underwriting Agreement [Member] | Series A Warrants [Member]
Subsequent Event [Line Items]
Adjusted exercise price of warrants	$ 2.99				$ 2.99